Searchable abstracts of presentations at key conferences in endocrinology

ea0086oc2.4 | Endocrine Cancer and Late Effects | SFEBES2022

Delta-like non-canonical Notch ligand 1 (DLK1) – a novel biomarker in adrenocortical carcinoma

Pittaway James , Mariniello Katia , Altieri Barbara , Sbiera Iuliu , Sbiera Silviu , Chung Teng-Teng , Abdel-Azziz Tarek , DiMarco Aimee , Palazzo Fausto , Akker Scott A. , Landwehr Laura-Sophie , Ronchi Cristina , Parvanta Laila , Drake William , Kroiss Matthias , Fassnacht Martin , Guasti Leonardo

Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options and a heterogenous prognosis. The histological diagnosis of ACC is complex and there is increasing interest in identifying and validating new immunohistochemical markers. Delta-like non-canonical Notch ligand 1 (DLK1) is a cleavable single-pass transmembrane protein. In humans, DLK1 is present in many tissues during foetal development, is restricted to progenitor/stem cells in a few adult tissue...

ea0090oc6.5 | Oral Communications 6: Endocrine-related Cancer | ECE2023

WEE1 kinase inhibitor, adavosertib (AZD1775), as a novel potential therapeutic strategy in advanced adrenocortical carcinoma

Tamburello Mariangela , Sbiera Silviu , Justus Weber , Lippert Juliane , Detomas Mario , Schauer Marc Philipp , Urlaub Hanna , Steinhauer Sonja , Kimpel Otilia , Landwehr Laura-Sophie , Constanze Hantel , Sigala Sandra , Ronchi Cristina , Hudecek Michael , Katja Kiseljak-Vassiliades , Fassnacht Martin , Altieri Barbara

Background: Adrenocortical cancer (ACC) is a rare malignant neoplasm with a dismal prognosis, particularly in advanced disease. For these patients only limited therapeutic options are available. Adavosertib (AZD1775) is a potent inhibitor of tyrosine kinase WEE1 that regulates cell cycle checkpoints, slowing cell cycle progression and leading to mitotic entry in the presence of DNA damage. Therefore, its use could potentiate existing DNA damage-based therapies. Here, we evalua...

ea0049gp5 | Adrenal 1 | ECE2017

Protein Kinase A signaling saves regulatory subunit IIβ from PRKACA mutation-mediated degradation

Weigand Isabel , Bathon Kerstin , Ronchi Cristina , Rizk-Rabin Marthe , Di Dalmazi Guido , Wild Vanessa , Rubin Beatrice , Vanselow Jens T , Schlosser Andreas , Calebiro Davide , Beuschlein Felix , Bertherat Jerome , Fassnacht Martin , Sbiera Silviu

Protein Kinase A (PKA) consists of two catalytic and two regulatory subunits with several isoforms (Cα,β,γ, RIα,IIα,Iβ,IIβ). In 30–40% of cortisol-producing adrenocortical adenomas (CPA) heterozygous activating somatic mutations in the catalytic subunit α (Cα) of PKA have been found. Previous reports found strikingly reduced levels of RIIβ in CPA compared to other adrenocortical tumors. Here, we investigated the correlatio...

ea0059oc1.6 | Translational highlights | SFEBES2018

Germline CYP2W1*6 and CYP2B6*6 polymorphisms as predicting markers of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicentric ENSAT study

Altieri Barbara , Herterich Sabine , Sbiera Silviu , Volante Marco , Francia Silvia De , Casa Silvia Della , Pontecorvi Alfredo , Quinkler Marcus , Kienitz Tina , Mannelli Massimo , Canu Letizia , Chortis Vasileios , Kaltsas Gregory , Kroiss Matthias , Terzolo Massimo , Fassnacht Martin , Ronchi Cristina L

Adrenocortical carcinoma (ACC) is a rare tumor with poor prognosis and the only approved drug for advanced disease is mitotane. The cytochromes P450 (CYP) 2W1 and 2B6 are proposed predicting markers of sensitivity to mitotane treatment. Aim of the study was to evaluate the relationship between CYP2W1 and/or CYP2B6 polymorphisms and response to mitotane in ACC.Methods: We performed a multicentric retrospective study including 182 ACC patients (F/M=121/61)...

ea0070yi3 | Young Investigators | ECE2020

RNA-sequencing of adrenocortical tumors reveals novel pathogenetic insights

Di Dalmazi Guido , Altieri Barbara , Scholz Claus , Sbiera Silviu , Luconi Michaela , Waldmann Jens , Kastelan Darko , Ceccato Filippo , Chiodini Iacopo , Arnaldi Giorgio , Osswald Andrea , Reincke Martin , Beuschlein Felix , Sauer Sascha , Fassnacht Martin , Appenzeller Silke , Ronchi Cristina

Background: Genetic alterations underlying the pathogenesis of autonomous cortisol secretion and early adrenocortical tumorigenesis have been identified in 40% of adrenocortical tumors (ACT). Nonetheless, the molecular events leading to development of ACT and steroid secretion remain obscure for a large proportion of patients.Aim: Aims of our study were to investigate the relationship between transcriptome profile and genetic background in a large series...

ea0070aep5 | Adrenal and Cardiovascular Endocrinology | ECE2020

Cytochrome P450 (CYP) 2W1 affect steroid secretion in adrenocortical cell line and tumor tissues

Altieri Barbara , Sbiera Silviu , Weigand Isabel , Volante Marco , Steinhauer Sonja , Lorey Antonia , Kendl Sabine , Kurlbaum Max , Herterich Sabine , Della Casa Silvia , Colao Annamaria , Terzolo Massimo , Kroiss Matthias , Fassnacht Martin , Ronchi Cristina

Background: The human cytochrome P450 (CYP) 2W1 is involved in the metabolism of several endogenous substrates, including lysophospholipids and fatty acids. Using a polyclonal antibody, we previously demonstrated a high CYP2W1 immunoreactivity in adrenocortical tumors, particularly in those secreting steroids. The aim of the study was to better elucidate the relationship between CYP2W1 and steroid secretion in adrenocortical carcinoma (ACC) H295R cell line and in a larger seri...

ea0022oc3.4 | Pituitary | ECE2010

Influence of the d3-GH receptor polymorphism on the metabolic and biochemical phenotype of GH deficient adults at baseline and during short- and long-term rhGH replacement therapy

Giavoli Claudia , Ferrante Emanuele , Profka Eriselda , Olgiati Luca , Bergamaschi Silvia , Ronchi Cristina L , Verrua Elisa , Filopanti Marcello , Passeri Elena , Montefusco Laura , Lania Andrea G , Corbetta Sabrina , Arosio Maura , Ambrosi Bruno , Spada Anna , Peccoz Paolo Beck

A common polymorphic variant of the GH receptor (exon-3 deletion, d3GHR) has been linked with increased response to recombinant human GH (rhGH) in some, but not all, GH deficient (GHD) and non-GHD patients. Aim of this study was to investigate the impact of the GHR genotype on the phenotype of GHD adults and on the metabolic effect of short- and long-term rhGH therapy, with particular focus on glucose homeostasis (1 year: n=100 and 5 years: n=50). Effects of rhGH...

ea0056oc11.1 | Clinical practice in endocrine tumours: combining conventional and molecular features | ECE2018

Targeted molecular analysis in adrenocortical carcinomas: a way towards improved personalized prognostication

Lippert Juliane , Appenzeller Silke , Liang Raimunde , Sbiera Silviu , Kircher Stefan , Altieri Barbara , Nanda Indrajit , Weigand Isabel , Gehrig Andrea , Steinhauer Sonja , Mueller Clemens , Kroiss Matthias , Rost Simone , Rosenwald Andreas , Fassnacht Martin , Ronchi Cristina

Adrenocortical carcinoma (ACC) has heterogeneous prognosis and no effective targeted therapies. Pan-genomic studies identified complex molecular patterns related to outcome. Our study aimed at identification of an ‘easy-to-apply’ molecular signature for better personalized prognostic stratification. A total of 107 ACC patients were enrolled. Clinical/histopathological parameters of prognostic relevance were evaluated. Targeted molecular analysis was performed on DNA ...

ea0056gp23 | Adrenal clinical | ECE2018

Nicotinamide Nucleotide Transhydrogenase as a novel treatment target in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela , Doig Craig , Walsh Mark , Meimaridou Eirini , Jenkinson Carl , Rodriguez-Blanco Giovanny , Ronchi Cristina , Jaffri Alisha , Metherell Louise , Hebenstreit Daniel , Dunn Warwick , Arlt Wiebke , Foster Paul

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating human NNT mutations result in congenital adrenal insufficiency. We hypothesized NNT silencing in ACC cells will i...

ea0056gp24 | Adrenal clinical | ECE2018

Germline CYP2W1*6 polymorphism is a new predictive marker of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicenter European study

Altieri Barbara , Herterich Sabine , Volante Marco , Sbiera Silviu , De Francia Silvia , Casa Silvia Della , Pontecorvi Alfredo , Quinkler Markus , Kienitz Tina , Mannelli Massimo , Canu Letizia , Chortis Vasileios , Kaltsas Gregory , Kroiss Matthias , Terzolo Massimo , Fassnacht Martin , Ronchi Cristina L

The cytochrome P450 2W1 (CYP2W1) is an orphan enzyme able to activate anticancer pro-drugs and to metabolise endogenous substances as fatty acids and lysophospholipids. Aim of the study was to evaluate the frequency of CYP2W1 polymorphisms in patients with adrenocortical carcinoma (ACC) and correlate it with the sensitivity to mitotane, which represents the only approved drug for the treatment of advanced ACC.Methods: A multicenter retrospective study in...